These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 2436687

  • 1. Kinetics of inhibition of human plasma kallikrein by a site-specific modified inhibitor Arg15-aprotinin: evaluation using a microplate system and comparison with other proteases.
    Scott CF, Wenzel HR, Tschesche HR, Colman RW.
    Blood; 1987 May; 69(5):1431-6. PubMed ID: 2436687
    [Abstract] [Full Text] [Related]

  • 2. Studies on the effect of serine protease inhibitors on activated contact factors. Application in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa.
    Tans G, Janssen-Claessen T, Rosing J, Griffin JH.
    Eur J Biochem; 1987 May 04; 164(3):637-42. PubMed ID: 3552674
    [Abstract] [Full Text] [Related]

  • 3. Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates.
    McRae BJ, Kurachi K, Heimark RL, Fujikawa K, Davie EW, Powers JC.
    Biochemistry; 1981 Dec 08; 20(25):7196-206. PubMed ID: 6976185
    [Abstract] [Full Text] [Related]

  • 4. Potent and selective Kunitz domain inhibitors of plasma kallikrein designed by phage display.
    Dennis MS, Herzka A, Lazarus RA.
    J Biol Chem; 1995 Oct 27; 270(43):25411-7. PubMed ID: 7592708
    [Abstract] [Full Text] [Related]

  • 5. Alpha 1-antitrypsin-Pittsburgh: a potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf.
    Scott CF, Carrell RW, Glaser CB, Lewis JH, Colman RW.
    Trans Assoc Am Physicians; 1985 Oct 27; 98():344-51. PubMed ID: 3879844
    [Abstract] [Full Text] [Related]

  • 6. Recombinant alpha 1-antitrypsin Pittsburgh (Met 358----Arg) is a potent inhibitor of plasma kallikrein and activated factor XII fragment.
    Schapira M, Ramus MA, Jallat S, Carvallo D, Courtney M.
    J Clin Invest; 1986 Feb 27; 77(2):635-7. PubMed ID: 3484756
    [Abstract] [Full Text] [Related]

  • 7. S2'-subsite variations between human and mouse enzymes (plasmin, factor XIa, kallikrein) elucidate inhibition differences by tissue factor pathway inhibitor -2 domain1-wild-type, Leu17Arg-mutant and aprotinin.
    Vadivel K, Kumar Y, Ogueli GI, Ponnuraj SM, Wongkongkathep P, Loo JA, Bajaj MS, Bajaj SP.
    J Thromb Haemost; 2016 Dec 27; 14(12):2509-2523. PubMed ID: 27797450
    [Abstract] [Full Text] [Related]

  • 8. Interaction of type 1 plasminogen activator inhibitor with the enzymes of the contact activation system.
    Berrettini M, Schleef RR, España F, Loskutoff DJ, Griffin JH.
    J Biol Chem; 1989 Jul 15; 264(20):11738-43. PubMed ID: 2787318
    [Abstract] [Full Text] [Related]

  • 9. Plant inhibitors of serine proteinases: Hageman factor fragment, kallikreins, plasmin, thrombin, factor Xa, trypsin, and chymotrypsin.
    Hojima Y, Pierce JV, Pisano JJ.
    Thromb Res; 1980 Oct 15; 20(2):163-71. PubMed ID: 6451948
    [No Abstract] [Full Text] [Related]

  • 10. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system.
    Hitomi Y, Ikari N, Fujii S.
    Haemostasis; 1985 Oct 15; 15(3):164-8. PubMed ID: 3161808
    [Abstract] [Full Text] [Related]

  • 11. Inhibitory effect of aprotinin and gabexate mesilate on human plasma kallikrein.
    Nakahara M.
    Arzneimittelforschung; 1983 Oct 15; 33(7):969-71. PubMed ID: 6194800
    [Abstract] [Full Text] [Related]

  • 12. Human plasma prekallikrein. Immunoaffinity purification and activation to alpha- and beta-kallikrein.
    Burger D, Schleuning WD, Schapira M.
    J Biol Chem; 1986 Jan 05; 261(1):324-7. PubMed ID: 2416749
    [Abstract] [Full Text] [Related]

  • 13. Active-site mapping of bovine and human blood coagulation serine proteases using synthetic peptide 4-nitroanilide and thio ester substrates.
    Cho K, Tanaka T, Cook RR, Kisiel W, Fujikawa K, Kurachi K, Powers JC.
    Biochemistry; 1984 Feb 14; 23(4):644-50. PubMed ID: 6370301
    [Abstract] [Full Text] [Related]

  • 14. Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor.
    Meijers JC, Kanters DH, Vlooswijk RA, van Erp HE, Hessing M, Bouma BN.
    Biochemistry; 1988 Jun 14; 27(12):4231-7. PubMed ID: 2844223
    [Abstract] [Full Text] [Related]

  • 15. Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition.
    Derechin VM, Blinder MA, Tollefsen DM.
    J Biol Chem; 1990 Apr 05; 265(10):5623-8. PubMed ID: 2138609
    [Abstract] [Full Text] [Related]

  • 16. Development of plasma kallikrein selective inhibitors.
    Okada Y, Tsuda Y, Tada M, Wanaka K, Hijikata-Okunomiya A, Okamoto U, Okamoto S.
    Biopolymers; 1999 Apr 05; 51(1):41-50. PubMed ID: 10380351
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Expression, isolation and characterization of recombinant [Arg15,Glu52]aprotinin.
    Auerswald EA, Hörlein D, Reinhardt G, Schröder W, Schnabel E.
    Biol Chem Hoppe Seyler; 1988 May 05; 369 Suppl():27-35. PubMed ID: 2462433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.